{"transactions":[{"id":744762,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:15:59.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264031/ownership.xml","form_type":"4"}},{"id":770374,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-20T20:13:38.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant."}],"balance_after":22000,"derivative":{"exercise_price":4.52,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001211840-26-000002","document":"wk-form4_1779308015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000121184026000002/wk-form4_1779308015.xml","form_type":"4"}},{"id":770373,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-20T20:13:38.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"}],"balance_after":3750,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001211840-26-000002","document":"wk-form4_1779308015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000121184026000002/wk-form4_1779308015.xml","form_type":"4"}},{"id":770372,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-20T20:13:38.000Z","date":"2026-05-18","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001211840-26-000002","document":"wk-form4_1779308015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000121184026000002/wk-form4_1779308015.xml","form_type":"4"}},{"id":770371,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:13:38.000Z","date":"2026-05-18","kind":"exercise","planned":false,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":47824,"source":{"system":"sec-edgar","filing":"0001211840-26-000002","document":"wk-form4_1779308015.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000121184026000002/wk-form4_1779308015.xml","form_type":"4"}},{"id":1125259,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-04T01:41:10.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35000,"derivative":{"exercise_price":11.96,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-081360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025081360/ownership.xml","form_type":"4"}},{"id":1137729,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-22T20:01:57.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant."}],"balance_after":22000,"derivative":{"exercise_price":1.49,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001125345-25-000078","document":"wk-form4_1747944109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000078/wk-form4_1747944109.xml","form_type":"4"}},{"id":1137728,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T20:01:57.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"}],"balance_after":3750,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001125345-25-000078","document":"wk-form4_1747944109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000078/wk-form4_1747944109.xml","form_type":"4"}},{"id":1137727,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-22T20:01:57.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001125345-25-000078","document":"wk-form4_1747944109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000078/wk-form4_1747944109.xml","form_type":"4"}},{"id":1137726,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T20:01:57.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":true,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":44074,"source":{"system":"sec-edgar","filing":"0001125345-25-000078","document":"wk-form4_1747944109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000078/wk-form4_1747944109.xml","form_type":"4"}},{"id":1502166,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-24T21:10:17.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":25133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":25133,"derivative":{"exercise_price":31.53,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":25133},"source":{"system":"sec-edgar","filing":"0000950170-24-064726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024064726/ownership.xml","form_type":"4"}},{"id":1504079,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T21:16:25.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant."}],"balance_after":16500,"derivative":{"exercise_price":4.26,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001125345-24-000127","document":"wk-form4_1716498965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000127/wk-form4_1716498965.xml","form_type":"4"}},{"id":1504078,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-23T21:16:25.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"}],"balance_after":6500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001125345-24-000127","document":"wk-form4_1716498965.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000127/wk-form4_1716498965.xml","form_type":"4"}},{"id":1505891,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-22T20:32:28.000Z","date":"2024-05-20","kind":"exercise","planned":false,"acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001125345-24-000101","document":"wk-form4_1716409937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000101/wk-form4_1716409937.xml","form_type":"4"}},{"id":1505890,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T20:32:28.000Z","date":"2024-05-20","kind":"exercise","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock."}],"balance_after":37574,"source":{"system":"sec-edgar","filing":"0001125345-24-000101","document":"wk-form4_1716409937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000101/wk-form4_1716409937.xml","form_type":"4"}},{"id":1791150,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T20:06:34.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":4.91,"value":73650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.90 to $4.91. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":33074,"source":{"system":"sec-edgar","filing":"0001125345-23-000111","document":"wk-form4_1693598784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000111/wk-form4_1693598784.xml","form_type":"4"}},{"id":1870563,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-06-02T20:58:13.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier"}],"balance_after":4500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001125345-23-000099","document":"wk-form4_1685739483.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000099/wk-form4_1685739483.xml","form_type":"4"}},{"id":1870562,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:58:13.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":4.67,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001125345-23-000099","document":"wk-form4_1685739483.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000099/wk-form4_1685739483.xml","form_type":"4"}},{"id":1878263,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-25T22:36:49.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":24900,"derivative":{"exercise_price":13.49,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001209191-23-032274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123032274/doc4.xml","form_type":"4"}},{"id":2099902,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":2.17,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099901,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":4.72,"expiration_date":"2030-12-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099900,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099899,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":6.9,"expiration_date":"2028-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099898,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":4.25,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099897,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":7.75,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099896,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":6200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":16.06,"expiration_date":"2025-11-19","underlying":"Common Stock","underlying_shares":6200},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099895,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":4688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":20.83,"expiration_date":"2024-12-19","underlying":"Common Stock","underlying_shares":4688},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099894,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"disposition_to_issuer","acquired":false,"shares":9375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":12,"expiration_date":"2024-03-26","underlying":"Common Stock","underlying_shares":9375},"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099893,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":1800,"ownership":{"direct":false,"nature":"By Hurwitz/Lichtenfeld Revocable Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer (\"Common Stock\"), without interest and less any applicable withholding taxes  (the \"Cash Consideration\"); and (2) one contingent value right (\"CVR\") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the \"Offer Price\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer (\"Common Stock\"), without interest and less any applicable withholding taxes  (the \"Cash Consideration\"); and (2) one contingent value right (\"CVR\") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the \"Offer Price\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2099892,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-01T09:19:33.000Z","date":"2022-11-30","kind":"other","acquired":false,"shares":25672,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer (\"Common Stock\"), without interest and less any applicable withholding taxes  (the \"Cash Consideration\"); and (2) one contingent value right (\"CVR\") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the \"Offer Price\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer (\"Common Stock\"), without interest and less any applicable withholding taxes  (the \"Cash Consideration\"); and (2) one contingent value right (\"CVR\") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the \"Offer Price\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-22-023026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299322023026/form4.xml","form_type":"4"}},{"id":2242572,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T20:05:56.000Z","date":"2022-06-03","kind":"grant","acquired":true,"shares":19596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":19596,"derivative":{"exercise_price":4.58,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":19596},"source":{"system":"sec-edgar","filing":"0001209191-22-034490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122034490/doc4.xml","form_type":"4"}},{"id":2260424,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-24T01:06:42.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant."}],"balance_after":18000,"derivative":{"exercise_price":3.9,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001125345-22-000064","document":"wf-form4_165335438800176.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000064/wf-form4_165335438800176.xml","form_type":"4"}},{"id":2488451,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-02T18:49:30.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal monthly installments over one year from the date of grant."}],"balance_after":14000,"derivative":{"exercise_price":2.17,"expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001062993-21-012053","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000106299321012053/form4.xml","form_type":"4"}},{"id":2693686,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T00:38:21.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":19596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders"}],"balance_after":19596,"derivative":{"exercise_price":19.56,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":19596},"source":{"system":"sec-edgar","filing":"0000899243-21-020988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924321020988/doc4.xml","form_type":"4"}},{"id":2710611,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T01:27:23.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":28.88,"expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001125345-21-000073","document":"wf-form4_162130122095194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534521000073/wf-form4_162130122095194.xml","form_type":"4"}},{"id":2937623,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T17:20:59.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal monthly installments over one year from the date of grant."}],"balance_after":12000,"derivative":{"exercise_price":4.72,"expiration_date":"2030-12-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001273636-20-000011","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363620000011/edgar.xml","form_type":"4"}},{"id":3023906,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":26176,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by MPM Asset Management Investors BV2018 LLC (\"MPM Asset Management\"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7893},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023905,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":70492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21254},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023904,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":1326313,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by MPM BioVentures 2018, L.P. (\"BV 2018\"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC (\"BV 2018 GP\"). MPM BioVentures 2018 LLC (\"BV 2018 LLC\") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":399867},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023903,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":275932,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by MPM Asset Management Investors BV2018 LLC (\"MPM Asset Management\"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":83188},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023902,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":743076,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":224025},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023901,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":13980992,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by MPM BioVentures 2018, L.P. (\"BV 2018\"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC (\"BV 2018 GP\"). MPM BioVentures 2018 LLC (\"BV 2018 LLC\") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4215076},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023900,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-08-07","kind":"purchase","acquired":true,"shares":26176,"price":2.811,"value":73580.736,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by MPM Asset Management Investors BV2018 LLC (\"MPM Asset Management\"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any."}],"balance_after":26176,"derivative":{"underlying":"Common Stock","underlying_shares":7893},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023899,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-08-07","kind":"purchase","acquired":true,"shares":70492,"price":2.811,"value":198153.012,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any."}],"balance_after":70492,"derivative":{"underlying":"Common Stock","underlying_shares":21254},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023898,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-08-07","kind":"purchase","acquired":true,"shares":1326313,"price":2.811,"value":3728265.843,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by MPM BioVentures 2018, L.P. (\"BV 2018\"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC (\"BV 2018 GP\"). MPM BioVentures 2018 LLC (\"BV 2018 LLC\") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1326313,"derivative":{"underlying":"Common Stock","underlying_shares":399867},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023897,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-07-31","kind":"purchase","acquired":true,"shares":96576,"price":1,"value":96576.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by MPM Asset Management Investors BV2018 LLC (\"MPM Asset Management\"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any."}],"balance_after":275932,"derivative":{"underlying":"Common Stock","underlying_shares":29116},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023896,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-07-31","kind":"purchase","acquired":true,"shares":260077,"price":1,"value":260077.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any."}],"balance_after":743076,"derivative":{"underlying":"Common Stock","underlying_shares":78409},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023895,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-07-31","kind":"purchase","acquired":true,"shares":4893347,"price":1,"value":4893347.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series A Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by MPM BioVentures 2018, L.P. (\"BV 2018\"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC (\"BV 2018 GP\"). MPM BioVentures 2018 LLC (\"BV 2018 LLC\") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any."}],"balance_after":13980992,"derivative":{"underlying":"Common Stock","underlying_shares":1475277},"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023894,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":91081,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by MPM Asset Management Investors BV2018 LLC (\"MPM Asset Management\"). The manager of MPM Asset Management is BV 2018 LLC. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC.  The Reporting Person disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any."}],"balance_after":91081,"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023893,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":245279,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of his pecuniary interest therein, if any."}],"balance_after":245279,"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3023892,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T22:55:07.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":4614943,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by MPM BioVentures 2018, L.P. (\"BV 2018\"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC (\"BV 2018 GP\"). MPM BioVentures 2018 LLC (\"BV 2018 LLC\") is the managing member of BV 2018 GP. The Reporting Person, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4614943,"source":{"system":"sec-edgar","filing":"0000899243-20-026170","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026170/doc4.xml","form_type":"4"}},{"id":3147540,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-15T20:37:07.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":24.97,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001125345-20-000090","document":"wf-form4_158957501009925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534520000090/wf-form4_158957501009925.xml","form_type":"4"}},{"id":3349592,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-06T17:50:02.000Z","date":"2019-12-04","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable on December 4, 2020."}],"balance_after":10000,"derivative":{"exercise_price":3.02,"expiration_date":"2029-12-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001273636-19-000045","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363619000045/edgar.xml","form_type":"4"}},{"id":3518827,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-20T21:48:52.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":18,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001125345-19-000075","document":"wf-form4_155838891757750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534519000075/wf-form4_155838891757750.xml","form_type":"4"}},{"id":3758664,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-11-19T19:33:11.000Z","date":"2018-11-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable on November 15, 2019."}],"balance_after":10000,"derivative":{"exercise_price":6.9,"expiration_date":"2028-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001273636-18-000067","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000067/edgar.xml","form_type":"4"}},{"id":3858952,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-30T21:25:20.000Z","date":"2018-07-25","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being amended to correct a scrivener's error with regards to the number of shares underlying the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable on July 25, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4 is being amended to correct a scrivener's error with regards to the number of shares underlying the option grant."}],"balance_after":10000,"derivative":{"exercise_price":4.25,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001273636-18-000040","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000040/edgar.xml","form_type":"4/A","original_submission_date":"2018-07-27"}},{"id":3859880,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-27T17:43:02.000Z","date":"2018-07-25","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable on July 25, 2019."}],"balance_after":8000,"derivative":{"exercise_price":4.25,"expiration_date":"2028-07-25","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001273636-18-000030","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000030/edgar.xml","form_type":"4"}},{"id":3915232,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-29T18:57:59.000Z","date":"2018-05-24","kind":"other","acquired":true,"shares":25672,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hurwitz/Lichtenfeld Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Alta Partners Management VIII, LLC, of which the Hurwitz/Lichtenfeld Revocable Trust is a non-managing member. The reporting person serves as a trustee and is a beneficiary of the Hurwitz/Lichtenfeld Revocable Trust."}],"balance_after":27472,"source":{"system":"sec-edgar","filing":"0001273636-18-000007","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000127363618000007/edgar.xml","form_type":"4"}},{"id":3924229,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-21T20:53:51.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":21.34,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001125345-18-000071","document":"wf-form4_152693601812675.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534518000071/wf-form4_152693601812675.xml","form_type":"4"}},{"id":4310242,"issuer":{"id":6104,"kind":"organization","name":"MACROGENICS INC","symbol":"MGNX"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-22T23:01:43.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":19.57,"expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001125345-17-000076","document":"wf-form4_149549408648847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534517000076/wf-form4_149549408648847.xml","form_type":"4"}},{"id":4408929,"issuer":{"id":121949,"kind":"organization","name":"APPLIED GENETIC TECHNOLOGIES CORP","symbol":"AGTC"},"owners":[{"id":40092,"kind":"person","name":"HURWITZ EDWARD","position":1,"cik":"0001211840","reported_name":"HURWITZ EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2017-03-02T19:23:50.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option becomes exercisable on February 28, 2018."}],"balance_after":8000,"derivative":{"exercise_price":7.75,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000899243-17-006168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1273636/000089924317006168/doc4.xml","form_type":"4"}}]}